Jefferies Downgrades Halozyme Therapeutics (HALO) to Hold
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $103.67 +0.65%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 26
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 26
Join SI Premium – FREE
Jefferies downgraded Halozyme Therapeutics (NASDAQ: HALO) from Buy to Hold with a price target of $10.00.
The firm comments, "Ahead of partnered products approval/launch (utilizing HALO's rHuPH20 technology), we assess commercial potential of SC Herceptin (EU oncologist survey), HyQvia (U.S. experts discussion), and SC MabThera (EU oncologists discussions). On likely slow market uptake/challenges, we downgrade HALO to Hold, particularly as we view ~5% royalty on sales to HALO unlikely to provide further upside from current valuation."
Jefferies cut FY12 EPS from ($0.53) to ($0.57) and FY13 EPS from ($0.32) to ($0.51).
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $12.15 yesterday.
The firm comments, "Ahead of partnered products approval/launch (utilizing HALO's rHuPH20 technology), we assess commercial potential of SC Herceptin (EU oncologist survey), HyQvia (U.S. experts discussion), and SC MabThera (EU oncologists discussions). On likely slow market uptake/challenges, we downgrade HALO to Hold, particularly as we view ~5% royalty on sales to HALO unlikely to provide further upside from current valuation."
Jefferies cut FY12 EPS from ($0.53) to ($0.57) and FY13 EPS from ($0.32) to ($0.51).
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $12.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Baird Downgrades Ramaco Resources Inc. (METC) to Neutral
- Nomura/Instinet Downgrades China Literature (772:HK) (CHLLF) to Neutral
Create E-mail Alert Related Categories
Analyst EPS Change, DowngradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
